Medicare Expands Coverage for Alzheimer's Drug Leqembi, Setting $26,500 Annual Price Point
核心洞察
Medicare (搜索) now covers 80% of Leqembi costs for eligible patients with mild Alzheimer's disease (搜索), requiring providers to participate in a coverage with evidence development registry.
The groundbreaking Alzheimer's treatment Leqembi demonstrated a 27% reduction in cognitive decline during the phase 3 Clarity AD trial, marking a significant advancement in treatment options.
Total treatment costs, including diagnostics and monitoring, may reach $70,000, though over 90% of Medicare (搜索) beneficiaries are expected to pay minimal out-of-pocket expenses through supplemental coverage.
Medicare (搜索) has announced comprehensive coverage details for Leqembi (lecanemab), the newly FDA-approved Alzheimer's treatment, marking a significant development in accessibility to innovative dementia therapies. The drug, priced at $26,500 for a year's supply by manufacturers Eisai and Biogen, will be covered under Medicare Part B for eligible patients.
Coverage Requirements and Patient Eligibility
Medicare (搜索) beneficiaries must meet specific criteria to qualify for Leqembi coverage. Patients must have a diagnosis of mild cognitive impairment or mild Alzheimer's disease (搜索), which affects approximately 15-20% of Alzheimer's patients, according to Dr. Barbara Joy Snider, a Washington University neurology professor who led one of the Clarity AD drug trials.
Healthcare providers must participate in a CMS-facilitated "coverage with evidence development" (CED) registry, ensuring continued data collection on the drug's effectiveness. This requirement may impact accessibility in regions lacking the necessary specialist infrastructure.
Financial Impact and Cost Sharing
Under Medicare (搜索) Part B, coverage includes 80% of Leqembi's cost after meeting the annual deductible ($257 in 2025). This translates to Medicare covering approximately $21,200 of the annual treatment cost, with patients responsible for the remaining 20% ($5,300) through out-of-pocket payments or supplemental insurance.
Clinical Efficacy and Treatment Protocol
The FDA's full approval of Leqembi in July 2023 was based on compelling results from the 18-month Clarity AD trial, which demonstrated a 27% reduction in cognitive decline among participants with mild Alzheimer's dementia. The treatment involves biweekly intravenous infusions and requires comprehensive monitoring.
Comprehensive Treatment Requirements
The full treatment protocol includes:
- Genetic testing for ARIA risk assessment
- PET scans to evaluate amyloid beta protein plaques
- Cerebrospinal fluid testing
- Regular monitoring with potential MRI scans
- Ongoing medical consultations
Cost Management and Accessibility
While total treatment costs, including diagnostics and monitoring, may approach $70,000, the Alzheimer's Association reports that over 90% of Medicare (搜索) beneficiaries will face minimal out-of-pocket expenses due to supplemental coverage through Medicaid, Medicare Advantage plans, or other insurance policies.
The coverage decision represents a crucial step in addressing the needs of the estimated 6.7 million U.S. adults aged 65 and older affected by Alzheimer's disease (搜索), offering a new option in the limited landscape of effective treatments for this progressive condition.